Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Collegium Pharmaceutical (COLL) Assets (2016 - 2025)

Collegium Pharmaceutical (COLL) has 10 years of Assets data on record, last reported at $1.6 billion in Q3 2025.

  • For Q3 2025, Assets fell 1.7% year-over-year to $1.6 billion; the TTM value through Sep 2025 reached $1.6 billion, down 1.7%, while the annual FY2024 figure was $1.7 billion, 45.51% up from the prior year.
  • Assets reached $1.6 billion in Q3 2025 per COLL's latest filing, up from $1.6 billion in the prior quarter.
  • Across five years, Assets topped out at $1.7 billion in Q4 2024 and bottomed at $646.1 million in Q1 2021.
  • Average Assets over 5 years is $1.2 billion, with a median of $1.2 billion recorded in 2022.
  • Peak YoY movement for Assets: skyrocketed 92.88% in 2022, then decreased 13.22% in 2024.
  • A 5-year view of Assets shows it stood at $692.1 million in 2021, then skyrocketed by 69.65% to $1.2 billion in 2022, then decreased by 2.63% to $1.1 billion in 2023, then surged by 45.51% to $1.7 billion in 2024, then decreased by 3.38% to $1.6 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Assets were $1.6 billion in Q3 2025, $1.6 billion in Q2 2025, and $1.6 billion in Q1 2025.